QLINE — Q-Line Biotech Share Price
Last trade - 00:00- IN₹11.94bn
- IN₹13.82bn
- IN₹6.28bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.21 | ||
| Price to Tang. Book | 5.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.9 | ||
| EV to EBITDA | 12.51 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 31.29% | ||
| Return on Equity | 28.78% | ||
| Operating Margin | 16.43% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | 6,083.58 | 3,654.73 | 4,072.92 | 6,275.61 | n/a | n/a | 1.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -41.66 | +6.46 | +9.86 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) and consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The Company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors, who in turn sell its products to hospitals/diagnostic centers or directly to diagnostic service providers and hospitals. It has developed a diversified product portfolio in the IVD industry which includes reagents, point of care devices and kits used in clinical chemistry, coagulation, hematology, HPLC, rapid/ELISA, molecular, diagnostic instruments, equipment, consumables and services. It markets these products in around 26 states and the Union Territory with specific focus on Utter Pradesh, Rajasthan, Madhya Pradesh, Kerala and Odisha.
Directors
- Ajay Mahanty EDR (48)
- Saurabh Garg CHM (55)
- Kuldeep Chowdhry EDR (53)
- Amita Garg NED (51)
- Abhay Agrawal NED (47)
- Ayush Garg NED (24)
- Yethadka Prabhakara EDR (63)
- Pravir Kumar NID (66)
- Abhishek Mishra NID (30)
- Meenal Gupta CFO (45)
- Akhand Singh CCO (35)
- Last Annual
- March 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- November 10th, 2010
- Public Since
- May 29th, 2026
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 23,328,199
- Address
- 298-281, Transport Nagar, LUCKNOW, 226023
- Web
- https://qlinebiotech.com
- Phone
- +91 5222435570
- Contact
- Akhand Singh
- Auditors
- RK Jagetiya & CO.
Similar to QLINE
Avience Biomedicals
National Stock Exchange of India
Borosil Scientific
National Stock Exchange of India
Entero Healthcare Solutions
National Stock Exchange of India
Fischer Medical Ventures
National Stock Exchange of India
Galaxy Medicare
National Stock Exchange of India
FAQ
As of Today at 21:52 UTC, shares in Q-Line Biotech are trading at IN₹511.70. This share price information is delayed by 15 minutes.
Shares in Q-Line Biotech last closed at IN₹511.70 and the price had moved by over the past 365 days. In terms of relative price strength the Q-Line Biotech share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreQ-Line Biotech does not currently pay a dividend.
Q-Line Biotech does not currently pay a dividend.
Q-Line Biotech does not currently pay a dividend.
To buy shares in Q-Line Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹511.70, shares in Q-Line Biotech had a market capitalisation of IN₹11.94bn.
Here are the trading details for Q-Line Biotech:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: QLINE
Based on an overall assessment of its quality, value and momentum Q-Line Biotech is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Q-Line Biotech. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹511.70, shares in Q-Line Biotech were trading -9.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Q-Line Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹511.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Q-Line Biotech's management team is headed by:
- Ajay Mahanty - EDR
- Saurabh Garg - CHM
- Kuldeep Chowdhry - EDR
- Amita Garg - NED
- Abhay Agrawal - NED
- Ayush Garg - NED
- Yethadka Prabhakara - EDR
- Pravir Kumar - NID
- Abhishek Mishra - NID
- Meenal Gupta - CFO
- Akhand Singh - CCO